CHOSA Oncology AB announces approved re-listing memorandum

CHOSA Oncology AB (publ) ("CHOSA" or the "Company"), formerly RhoVac, announces that Spotlight Stock Market ("Spotlight") today approved the relisting memorandum that the Company was required to draw up in connection with the Company's reverse acquisition of the Danish CHOSA ApS.The approval of the re-listing memorandum also confirms that Spotlight considers CHOSA to meet all current listing requirements. As a result, trading in the Company's shares will be re-listed on the ordinary list.

CHOSA, which through the reverse acquisition of CHOSA ApS now owns the licensing rights to the drug development program "iCIP™", has during the spring of 2023 been working on preparing a re-listing memorandum and implementing procedures to ensure that the expanded group complies with the regulations for listed companies on Spotlight Stock Market.

Approved re-listing
Spotlight has now announced the approval of CHOSA's re-listing memorandum and announced the intention to move the Company’s share from the observation list. With the approval of the re-listing memorandum, Spotlight also verifies that CHOSA Oncology meets all current listing requirements.

Sedermera Corporate Finance AB acted as a financial advisor to CHOSA ApS in the reverse acquisition with RhoVac AB. Sedermera has also provided project management to CHOSA Oncology in the re-listing process and assisted in the preparation of the re-listing memorandum.

The re-listing memorandum can be found on the Company's (www.chosaoncology.com), Sedermera's (www.sedermera.se), and Spotlight's (www.spotlightstockmarket.com) respective websites.